---
ID: 3000
post_title: 'Malignant Hyperthermia Crisis &#8211; MH (10Cs)'
post_name: malignant-hyperthermia-crisis-mh
post_date: 2018-12-29 14:28:46
layout: page
link: >
  https://safetotsstage.wpengine.com/professionals/crisis-10c/malignant-hyperthermia-crisis-mh/
published: true
tags: [ ]
categories:
  - Uncategorized
---
[text-blocks id="header_crisis"] ←  [previous (Local anaesthetic systemic toxicity - LAST)][1]      |       [next (Can´t Oxygenate - Can´t Ventilate)][2]  → 
## Summary Malignant Hyperthermia crisis occurs in response to volatile anaesthetic agents and depolarising muscle relaxants (suxamethonium). Prevention and immediate treatment with dantrolene is life saving. 

## Background

*   Malignant hyperthermia is a life-threatening metabolic response to volatile anaesthetic agents or succinylcholine (suxamethonium). Previous uneventful exposure to these agents does not guarantee safe use
*   Mortality may approach 70% if untreated, with dantrolene treatment mortality approximates 3-5%

## Prevention

*   Recognition of patients at risk through careful medical and family history and/ or consultation with specialist Malignant Hyperthermia reference centre
*   Do not use volatiles or succinylcholine (suxamethonium) in patients at risk. Reduce preoperative anxiety
*   Use a vapour free anaesthetic machine if possible, if not available prepare machine according to manufacturer’s guidelines and use a new breathing circuit, rebreathing bag, and gas sampling tubes
*   Consider vapour scavenging filters
*   Ensure dantrolene availability

## Treatment

**Call for help early, initiate action plan and allocate specific tasks:** 
*   Stop potential trigger agents immediately and give 100% oxygen
*   Consider installing clean breathing system, remove inhalational agents and increase fresh gas flow to maximum, consider vapour scavenging filters
*   Hyperventilate to achieve normocapnia
*   Maintain anaesthesia using non-volatile anaesthetics and opioids as well as non-depolarising muscle relaxants, curtail surgery if possible
*   Give Dantrolen (2.5mg/kg every 5 minutes until effect - max 20mg/kg): need to assign one person to correctly reconstitute dantrolene from powder formulation
*   Active cooling
*   Treat or prevent hyperkalaemia, acidosis, arrhythmias (no calcium channel antagonists) and prevent acute renal failure and coagulopathy
*   Continuous monitoring of vital signs including peripheral and core temperature, invasive monitoring for repeated blood sampling
*   Check plasma CK

## Post Care

*   Continue monitoring postoperatively on PICU, repeat dantrolene as required
*   Repeat plasma CK
*   Monitor and prevent acute renal failure and compartment syndrome
*   Counsel patient and family members
*   Arrange referral to Malignant Hyperthermia Unit

## References

1.  Salazar JH, Yang J, Shen L, Abdullah F, Kim TW. Pediatric malignant hyperthermia: risk factors, morbidity, and mortality identified from the Nationwide Inpatient Sample and Kids' Inpatient Database. [*Paediatr Anaesth. 2014; 24: 1212-6.*][3]
2.  Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant Hyperthermia Susceptibility and Related Diseases. [*Anesthesiology. 2018; 128: 159-67.*][4]
3.  Cummings T, Der T, Karsli C. Repeated non-anesthetic malignant hyperthermia reactions in a child. [*Paediatr Anaesth. 2016; 26: 1202-3.*][5]
4.  Shapiro F, Athiraman U, Clendenin DJ, Hoagland M, Sethna NF. Anesthetic management of 877 pediatric patients undergoing muscle biopsy for neuromuscular disorders: a 20-year review. [*Paediatr Anaesth. 2016; 26: 710-21.*][6]
5.  Wappler F. S1-Leitlinie maligne Hyperthermie. [*Der Anaesthesist 2018; 67: 529–32.*][7]
6.  AAGBI. Malignant Hyperthermia Crisis. AAGBI Safety Guideline. <https://www.aagbi.org/publications/publications-guidelines/M/R>
7.  Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, Müller CR, Urwyler A; European Malignant Hyperthermia Group. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. [*Br J Anaesth 2015; 115: 531-9.*][8] [text-blocks id="footer_crisis"] [text-blocks id="footer_nav_professional"]  

 [1]: /safetots-crisis-sops/local-anaesthetic-systemic-toxicity-last/
 [2]: /safetots-crisis-sops/cant-oxygenate-cant-ventilate/
 [3]: https://www.ncbi.nlm.nih.gov/pubmed/24974921
 [4]: https://www.ncbi.nlm.nih.gov/pubmed/28902673
 [5]: https://www.ncbi.nlm.nih.gov/pubmed/27562486
 [6]: https://www.ncbi.nlm.nih.gov/pubmed/27111691
 [7]: https://www.awmf.org/uploads/tx_szleitlinien/001-008l_S1_Therapie-maligne-Hyperthermie_2018-03_1.pdf
 [8]: https://www.ncbi.nlm.nih.gov/pubmed/26188342